Antihistamines can influence immunotherapy response by enhancing T cell activation
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors. The preclinical study demonstrated that the histamine receptor H1 (HRH1) acts in tumor-associated macrophages (TAMs) to suppress T cell activation in the tumor microenvironment. The findings were published today in Cancer...
MD Anderson Research Highlights: SITC 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research...